In a disappointing finding from the REAL study, little difference was shown in visceral fat levels from those who shifted to atazanavir/ritonavir versus those remaining on their existing boosted protease inhibitor.

The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistant HIV, all of which are now available in Australia.

A warning has been issued by Tibotec, the manufacturers of Prezista (darunavir) regarding the risk of developing drug- induced hepatitis while taking the treatment.

John Daye, NAPWA's Health, Treatments & Research Portfolio Co-Convenor reports from the 15th Conference on Retroviruses and Opportunistic Infections (CROI) held in Boston, USA from 3-6 February 2008

Following consultation with the Therapeutic Goods Administration, Roche Pharmaceuticals is undertaking a sponsor initiated recall of all batches and presentations of Viracept (Nelfinavir).

A major scientific conference on HIV has wound up with promising news on treatments which could signal a significant improvement in HIV treatment for the first time in some years.

Finding effective treatment options for people who have taken many treatments and have multiple resistance mutations continues to be a significant challenge for HIV clinicians, and their patients.

HIV-related news in brief from the December 2006 edition of Positive Living.

The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports.

A new, more convenient and better-tolerated version of the protease inhibitor Kaletra (lopinavir/ritonavir) is now available for S100 prescription on the PBS. The new formulation comes in tablet form, requires no refrigeration and reduces the number of pills taken per day from six to four.